FREMONT, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Seeking to expand the knowledge base surrounding spectral flow cytometry, Cytek Biosciences, Inc. (CTKB) (Nasdaq: CTKB), a leading cell analysis ...

Earlier this month, Cytek Biosciences reported third quarter results, posting revenue of US$52.29 million and a net loss of US$5.48 million, as well as reaffirming its full-year 2025 revenue guidance.

America's Growth Leaders Cytek Biosciences has been recognized by TIME as one of America’s Growth Leaders of 2026. Presented in partnership with global data firm Statista, the ranking recognizes the ...

FREMONT, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- With cancer research and diagnostics driving the need for deeper, faster cellular insights, spectral flow cytometry leader Cytek Biosciences, Inc.

Cytek Biosciences has recurring revenue growth, improving margins, and ample cash that should continue compounding ...

KANSAS CITY, Kan.--(BUSINESS WIRE)--KCAS Bio continues to deliver against both growth objectives and more integrated customer service offerings. KCAS Bio has partnered with Crux Biolabs, a leading ...

FREMONT, Calif. and BARCELONA, Spain, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, has signed an agreement with the Centre for ...

Recognized as a pioneer in spectral flow cytometry, Cytek is the creator of the first commercialized fluorescence-based flow cytometry platform to achieve 40 colors – effectively shifting the paradigm ...